Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexander Seng

Nurse Practitioner Pottstown, PA Nurse Practitioner

NPI 1891340048 CMS profile 11146745

1591 Medical Dr, Pottstown, PA 19464

Open in the dashboard

General payments

$19,199

653 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Seng of Pottstown, PA is reported in the CMS Open Payments database as having received $19,199 across 653 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,831 25
2024 General $3,190 64
2023 General $5,094 207
2022 General $4,962 189
2021 General $4,123 168

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Seng
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Alexander Seng were reported at $1,831. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Alexander Seng Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,123 $135 $40–$426 $132
2022 $4,962 $152 $48–$470 $149
2023 $5,094 $166 $54–$529 $160
2024 $3,190 $173 $55–$556 $164
2025 $1,831 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $4,229 125 payments
  2. GlaxoSmithKline, LLC. $2,343 81 payments
  3. Jazz Pharmaceuticals Inc. $2,172 43 payments
  4. Actelion Pharmaceuticals US, Inc. $1,422 70 payments
  5. Regeneron Healthcare Solutions, Inc. $1,041 28 payments
  6. Genzyme Corporation $900 29 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $795 33 payments
  8. United Therapeutics Corporation $694 19 payments
  9. Novartis Pharmaceuticals Corporation $496 28 payments
  10. Harmony Biosciences LLC $473 17 payments
  11. Other $4,633 180 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $18,378 647 payments
  2. Consulting Fee $585 2 payments
  3. Education $236 4 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $1,891 42 payments
  2. FASENRA $1,858 50 payments
  3. XYWAV $1,728 30 payments
  4. UPTRAVI $1,422 70 payments
  5. OPSUMIT $1,346 65 payments
  6. NUCALA $1,269 45 payments
  7. DUPIXENT Immunology $1,157 31 payments
  8. DUPIXENT Inflammation And Immunology $1,041 28 payments
  9. TEZSPIRE $778 27 payments
  10. TRELEGY ELLIPTA $646 32 payments
  11. Other $9,072 361 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

659

Median for Nurse Practitioner: 389

Drug cost

$232,357

Median for Nurse Practitioner: $21,885

Branded share of claims

76.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 135 $102,948
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 45 $34,071
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 49 $25,148
Spiriva Respimat Tiotropium Bromide Brand 18 $12,297
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 12 $11,377
Breo Ellipta Fluticasone/Vilanterol Brand 26 $10,652
Incruse Ellipta Umeclidinium Bromide Brand 20 $9,624
Symbicort Budesonide/Formoterol Fumarate Brand 24 $6,206
Advair Hfa Fluticasone Propion/Salmeterol Brand 14 $5,863
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 45 $5,641

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$7,947

Medicare's payments for the services billed

Medicare patients

135

Average age 75

Services billed

201

74 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 41%
Diabetes 39%
COPD 39%
Atrial fibrillation 33%
Heart failure 27%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $484
$484 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $330
$330 — —
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $317
$317 — —
AREXVY
  • GlaxoSmithKline, LLC. $286
$286 — —
NUCALA
  • GlaxoSmithKline, LLC. $280
$280 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

653 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record